radiprodil + carbamazepine

Radiprodil + carbamazepine is a **combination therapy** under investigation for its pharmacokinetic interactions and safety in humans. **Radiprodil** is a selective negative allosteric modulator of the **GluN2B subunit of the NMDA receptor**, being developed primarily for neurological disorders with a focus on seizure control, particularly in disorders related to GRIN2A and GRIN2B mutations. **Carbamazepine** is a well-established antiseizure medication that acts primarily as a **voltage-dependent sodium channel blocker**, widely used for epilepsy, trigeminal neuralgia, and bipolar disorder. Current clinical research examines the effect of carbamazepine (a strong CYP3A4 inducer) on the pharmacokinetics, safety, and tolerability of radiprodil in healthy adults. The combination is being studied primarily in the context of neurological and seizure disorders, including tuberous sclerosis complex and focal cortical dysplasia[1][3][4][5].